Rezolute Announces Alignment With FDA On Streamlined Design For Ongoing Phase 3 Trial Of Ersodetug In Tumor Hyperinsulinism

RefinitivThời gian đọc: dưới 1 phút

Rezolute Inc RZLT:

REZOLUTE ANNOUNCES ALIGNMENT WITH FDA ON STREAMLINED DESIGN FOR ONGOING PHASE 3 TRIAL OF ERSODETUG IN TUMOR HYPERINSULINISM
REZOLUTE INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026
REZOLUTE INC - FDA CONFIRMS SUNRIZE TRIAL RESULTS EXPECTED IN DEC 2025 AS CLINCIAL EVIDENCE

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Đăng nhập hoặc tạo tài khoản miễn phí trọn đời để đọc tin tức này